Related Experiment Video
Updated: Feb 12, 2026
Cardiac Magnetic Resonance Imaging at 7 Tesla
Published on: January 6, 2019
The role of JAK2 inhibitors in MPNs 7 years after approval
Francesco Passamonti1,2, Margherita Maffioli2
1Dipartimento di Medicina e Chirurgia, University of Insubria, Varese, Italy; and.
Abstract:
Myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia vera (PV), and primary myelofibrosis (MF). Phenotype-driver mutations of JAK2, CALR, and MPL genes are present in MPNs and can be variably combined with additional mutations. Driver mutations entail a constitutive activation of the JAK2/STAT pathway, the key signaling cascade in MPNs. Among JAK2 inhibitors (JAKis), ruxolitinib (RUX) has been approved for the treatment of intermediate and high-risk MF and for PV inadequately controlled by or intolerant of hydroxyurea. Other JAKis, such as fedratinib and pacritinib, proved to be useful in MF. The primary end points in MF trials were spleen volume response (SVR) and symptom response, whereas in PV trials they were hematocrit control with or without spleen response. In advanced MF, RUX achieved a long lasting SVR of >35% in ∼60% of patients, establishing a new benchmark for MF treatment. RUX efficacy in early MF is also remarkable and toxicity is mild. In PV, RUX achieved hematocrit control in ∼60% of cases and SVR in 40%. Symptom relief was evident in both conditions. In the long-term, however, many MF patients lose their SVR. Indeed, the definition of RUX failure and the design of new trials in this setting are unmet needs. Decrease of hemoglobin/platelet levels and increased infection rates are the most common side effects of RUX, and nonmelanoma skin tumors need to be monitored while on treatment. In conclusion, the introduction of JAKis raises the bar of treatment goals in MF and PV.
Insights
JAK inhibitors like ruxolitinib offer significant spleen and symptom control for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). However, long-term efficacy challenges and side effects require ongoing monitoring and research.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Myeloproliferative neoplasms (MPNs), including essential thrombocythemia, polycythemia vera (PV), and primary myelofibrosis (MF), are driven by mutations in genes like JAK2, CALR, and MPL.
- These mutations lead to constitutive activation of the JAK2/STAT pathway, a critical signaling cascade in MPN pathogenesis.
- JAK inhibitors (JAKis) have emerged as a therapeutic option for MPNs, with ruxolitinib (RUX) approved for specific MF and PV patient populations.
Purpose of the Study:
- To evaluate the efficacy and safety of JAK inhibitors, particularly ruxolitinib, in treating myelofibrosis (MF) and polycythemia vera (PV).
- To assess the impact of JAK inhibitors on primary endpoints such as spleen volume response (SVR) and hematocrit control.
- To identify unmet needs in JAK inhibitor therapy for MPNs, including treatment failure and optimal trial design.
Main Methods:
- Review of clinical trial data for JAK inhibitors (ruxolitinib, fedratinib, pacritinib) in patients with MF and PV.
- Analysis of primary endpoints including spleen volume response (SVR), symptom response, and hematocrit control.
- Evaluation of treatment-related side effects and long-term outcomes.
Main Results:
- Ruxolitinib demonstrated significant and durable spleen volume response (>35%) in approximately 60% of advanced MF patients and achieved hematocrit control in about 60% of PV patients.
- Symptom relief was observed in both MF and PV patients treated with JAK inhibitors.
- Common side effects include decreased hemoglobin/platelet levels, increased infection rates, and a need for monitoring nonmelanoma skin tumors.
Conclusions:
- JAK inhibitors, exemplified by ruxolitinib, have significantly advanced treatment goals for MF and PV, offering substantial clinical benefits.
- Despite efficacy, challenges remain, including the long-term durability of spleen volume response in MF and the management of side effects.
- Further research is needed to define JAK inhibitor failure and optimize future clinical trial designs for MPN therapies.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:02Role of Septins
Cellular Functions of Septins
Recent studies have revealed the multifaceted roles of septins in various cellular processes such as cytokinesis, ciliogenesis, and neurogenesis. Septins act as scaffolds and...
01:23The Role of Culture
01:23Dipeptidyl Peptidase 4 Inhibitors
01:21Role-Based Identity